Clinical Study of ATTR-CM

Clinical Study Protocol of Transthyroxine Protein Amyloidosis Cardiomyopathy and Its Gene Carriers

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04935021

Enrollment

100

Registered

2021-06-22

Start date

2021-06-01

Completion date

2031-06-01

Last updated

2023-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transthyroxine Amyloidosis Cardiomyopathy

Brief summary

In this study, patients with ATTR-CM or gene carriers were selected to study the diagnosis and treatment, and long-term follow-up was conducted.

Interventions

DRUGATTR-CM

Current treatment

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients and gene carriers of ATTR-CM confirmed in the Second Affiliated Hospital of Zhejiang University School of Medicine, regardless of gender, age 18-90 years old; * Patients who have the ability to understand the test and can cooperate with investigators

Exclusion criteria

* Patients who unable to understand or unwilling to fill in informed consent forms or follow visitors

Design outcomes

Primary

Measure	Time frame	Description
Rate of cardiovascular death, myocardial infarction, and stroke	10 year	Primary Outcome

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026